Login to Your Account



New Acceleron, Celgene Deal Anything But 'Anemic'

By Catherine Shaffer


Thursday, August 4, 2011
Celgene Corp. will pay $25 million up front to Acceleron Pharma Inc. plus up to $217 million more in potential milestones, under a new collaboration agreement between the two companies for the development of an anemia therapeutic.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription